Randomized study of kezhi Capsules in Treating Nonalconolic Fatty Liver
10.3969/j.issn.1006-5725.2014.04.048
- VernacularTitle:壳脂胶囊治疗非酒精性脂肪肝的随机对照研究
- Author:
Yuewu YANG
;
Gemin XIAO
;
Baiming ZHAO
;
Hongzhi YANG
;
Min DAI
;
Lichun TENG
- Publication Type:Journal Article
- Keywords:
NAFLD;
Kezhi capsule;
Xuezhikang
- From:
The Journal of Practical Medicine
2014;(4):638-640
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the effect and side effects of Kezhi capsule in short-term treatment of nonalcoholic fatty liver disease (NAFLD). Methods 60 NAFLD cases of outpatients according to the inclusion criteria of were randomly assigned to two groups: the treated group-30cases with the prescription of Kezhi capsule , and the control group-30cases with the prescription of Xuezhikang. The treatment Course of taking Kezhi capusule (1.25 g, tid, po) and Xuezhikang(0.6 g, bid, po)was 24 weeks. Results After treatment in both groups we saw the significant decrease of the levels of ALT, AST, TC, TG, LDL-C, CREAT, BUN, BMI and TCM Syndromes scores, and the improvement of the ultrasonographic findings of liver steatosis. In the Xuezhikang group we saw higher decrease of TC and TG than the Kezhi capsule group with statistic difference (P < 0.05), while in Kezhi capsule group we saw higher decrease of BMI , TCM Syndromes scores and the improvement of the ultrasonographic findings of liver steatosis than the xuezhikang group with statistic difference (P < 0.05). Conclusions The results show that kezhi capsule is effective for the treatment of NAFLD without obvious side effects.
